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Abstract The paired helical filament, which comprises the 
major fibrous element of the neurofibrillary lesions of Alzhei-
mer's disease, is composed of hyperphosphorylated microtubule-
associated protein tau. Many of the hyperphosphorylated sites in 
tau are serine/threonine-prolines. Here we show that the stress-
activated protein (SAP) kinases SAPKly (also called JNK1), 
SAPK2a (also called p38, RK, CSBPs, Mpk2 and Mxi2), 
SAPK2b (also called p38ß), SAPK3 (also called ERK6 and 
p38y) and SAPK4 phosphorylate tau at many serine/threonine-
prolines, as assessed by the generation of the epitopes of 
phosphorylation-dependent anti-tau antibodies. Based on initial 
rates of phosphorylation, tau was found to be a good substrate 
for SAPK4 and SAPK3, a reasonable substrate for SAPK2b and 
a relatively poor substrate for SAPK2a and SAPKly. Phospho-
rylation of tau by SAPK3 and SAPK4 resulted in a marked 
reduction in its ability to promote microtubule assembly. These 
findings double the number of candidate protein kinases for the 
hyperphosphorylation of tau in Alzheimer's disease and other 
neurodegenerative disorders. 
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phatase 2A [12,18,19] is a candidate phosphatase. Of the 
above protein kinases, only MAP kinase phosphorylates re-
combinant tau at S422 [10]. Additional members of the MAP 
kinase family have been identified which are activated by cel-
lular stresses (chemical, heat and osmotic shock, UV irradia-
tion, inhibitors of protein synthesis), by bacterial lipopolysac-
charide and by the cytokines interleukin-1 and tumour 
necrosis factor, and have, therefore, been called stress-acti-
vated protein kinases or SAPKs (reviewed in [20]). In view 
of their relatedness to MAP kinase, we have investigated the 
phosphorylation of tau protein by SAPKs. 
In this paper we show that activated recombinant SAPKly 
(also called JNK1), SAPK2a (also called p38, p40, RK, 
CSBPs and Mxi2), SAPK2b (also called p38ß), SAPK3 (also 
called ERK6 and p38y) and SAPK4 phosphorylate recombi-
nant tau protein at multiple Ser/Thr-Pro sites that are hyper-
phosphorylated in PHF-tau, with SAPK4 and SAPK3 being 
the most effective. Phosphorylation of tau by SAPK3 and 
SAPK4 resulted in a marked reduction in the ability of tau 
to promote microtubule assembly. 
2. Materials and methods 
1. Introduction 
Abundant neurofibrillary lesions made of paired helical fil-
aments (PHFs) constitute one of the major neuropathological 
hallmarks of Alzheimer's disease and other neurodegenerative 
disorders. Hyperphosphorylated microtubule-associated pro-
tein tau (PHF-tau) is the major component of the PHF (re-
viewed in [1]). Extensive protein chemical and immunochem-
ical studies have identified about 20 hyperphosphorylated 
amino acids in PHF-tau, almost all of which flank the micro-
tubule-binding repeats [2-6]. Approximately half of these sites 
are serine/threonine-prolines [6]. Phosphorylation at many of 
these sites occurs in a significant fraction of fetal tau [5,7,8] 
and studies using biopsy-derived tau have shown that they are 
also phosphorylated in a small fraction of tau from adult 
human brain [9]. However, some sites, such as S422 [10], are 
only phosphorylated in PHF-tau. 
Hyperphosphorylation of tau could result from an in-
creased activity of tau kinases or the decreased activity of 
tau phosphatases. Mitogen-activated protein (MAP) kinase 
[11,12], neuronal cdc2-like kinase (NCLK) [13,14] and glyco-
gen synthase kinase-3 (GSK3) [15-17] are candidate protein 
kinases for the hyperphosphorylation of tau and protein phos-
2.1. Protein kinases 
The open reading frame of human SAPKly (also called JNK1 [21]) 
was amplified by PCR, verified by DNA sequencing and subcloned 
into the (His)e-tagged vector pRSET Xpress (Invitrogen). 6-His-
SAPKly was expressed in E. coli and purified by affinity chromatog-
raphy using ProBond (Invitrogen). Murine GST-MKK4 (a gift from 
Dr. I.R. Woodgett, Ontario Cancer Institute, Toronto, Ont., Canada) 
was expressed in E. coli and purified by affinity chromatography on 
glutathione-agarose. The GST-MKK4 (1 uM) was activated by incu-
bation for 60 min at 30°C with 0.1 mg/ml active MalE-MEK kinase (a 
MalE fusion with the kinase domain of MEK kinase, a gift from Dr. 
A.R. Nebreda, EMBL, Heidelberg, Germany) in 50 mM Tris-HCl, 
pH 7.5, 0.1 mM EGTA, 0.5 mM sodium orthovanadate, 0.03% (w/v) 
Brij 35, 0.1% (v/v) 2-mercaptoethanol, 5% (v/v) glycerol, 10 mM mag-
nesium acetate and 0.1 mM ATP. Activated GST-MKK4 was used to 
activate 6-His-SAPKly which was assayed routinely by the phospho-
rylation of GST-ATF2(19-96) (a gift from Dr. N. Jones, ICRF, Lon-
don, UK). One unit of activity was that amount of enzyme which 
incorporated 1 nmol phosphate into GST-ATF2 in 1 min. MalE-
Mpk2, the Xenopus homologue of SAPK2a (a gift from Dr. A.R. 
Nebreda [22]), human GST-SAPK2b [23,24], rat GST-SAPK3 [25] 
and human GST-SAPK4 [24] were expressed in E. coli and purified 
as described previously [24]. SKK3 (also called MKK6) was purified 
from rabbit skeletal muscle [26] and used to activate MalE-Mpk2, 
GST-SAPK2b, GST-SAPK3 and GST-SAPK4, as described previ-
ously [24], SAPK2a, SAPK2b, SAPK3 and SAPK4 were assayed rou-
tinely by the phosphorylation of myelin basic protein (MBP). One 
unit of activity was that amount of enzyme which incorporated 
1 nmol phosphate into MBP in 1 min. 
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Fig. 1. Epitopes of phosphorylation-dependent anti-tau antibodies. A: Schematic drawing of the 441 amino acid isoform of human brain tau 
with phosphorylated amino acids recognised by phosphorylation-dependent anti-tau antibodies. The microtubule-binding repeat region of tau is 
shown in white. B: Phosphorylated residues in tau recognised by each phosphorylation-dependent monoclonal anti-tau antibody. With the ex-
ception of 12E8 all these antibodies recognise S/T-P sites in tau. 
2.2. Phosphorylation assays 
The 441 amino acid isoform of human brain tau was expressed in 
E. coli from cDNA clone htau40 [27] and purified as described [28]. 
Phosphorylation assays (0.025 ml) were carried out at 30°C and com-
prised 25 mM Tris-HCl, pH 7.4, 0.1 mM EGTA, 0.1 mM sodium 
orthovanadate, 2.5 uM PKI (a specific inhibitor of cyclic AMP-de-
pendent protein kinase), protease inhibitors (0.5 mM phenylmethyl-
sulphonyl fluoride, 5 |ig/ml aprotinin, 5 (xg/ml leupeptin and 0.5 |xg/ml 
pepstatin), tau protein (2 uM) or myelin basic protein (2 |0.M), 10 mM 
magnesium acetate, 2 mM [y^PJATP (approximately 106 cpm/nmol) 
and activated SAPKly, SAPK2a, SAPK2b, SAPK3 or SAPK4 (0.2 VI 
ml or 1 U/ml). Reactions were initiated with ATP and aliquots were 
removed after various times ranging from 2 min to 18 h and used for 
SDS-PAGE and immunoblotting. Immunoblots were performed as 
described [12]. Alternatively, incorporation of 32P-radioactivity was 
measured after adsorption to Whatman P81 paper, as described 
[12]. In some experiments 100 |ig/ml heparin or dextran sulphate 
were included in the assays. 
2.3. Micro tubule assembly 
Non-phosphorylated htau40 (2 uM) and htau40 phosphorylated 
with 1 U/ml SAP kinase-3 or SAP kinase-4 was incubated with tubu-
lin (10 |xM, Cytoskeleton Inc.) in assembly buffer (80 mM PIPES, 
1 mM MgCl2, 1 mM EGTA, 1 mM dithiothreitol, 1 mM GTP, pH 
6.8) at 37°C. Polymerisation of microtubules was monitored by meas-
uring the absorbance at 350 nm. 
3. Results 
Tau protein incubated with 1 U/ml of each SAP kinase for 
18 h incorporated 2 mol phosphate/mol tau (SAPKly), 4 mol 
phosphate/mol tau (SAPK2a), 8 mol phosphate/mol tau 
(SAPK2b), 11 mol phosphate/mol tau (SAPK3) and 14 mol 
phosphate/mol tau (SAPK4). Similar differences between the 
five SAP kinases (each used at 0.2 U/ml) were observed when 
initial rates of tau phosphorylation were measured relative to 
the standard substrates MBP and ATF2 (Table 1). 
High stoichiometric ratios required long incubation periods 
and resulted in the generation of the epitopes of phosphoryl-
ation-dependent anti-tau antibodies (see Fig. 1 for antibody 
epitopes). Tau phosphorylated by individual SAP kinases 
showed a variable reduction in gel mobility, as seen by 
SDS-PAGE and immunoblotting with anti-tau serum 134 
which recognises the carboxy-terminus of tau in a non-phos-
phorylation-dependent manner [29] (Fig. 2). Thus, whereas 
tau phosphorylated by SAPKly showed almost no shift, tau 
phosphorylated by SAPK4 ran at 75 kDa apparent molecular 
mass compared to 67 kDa for non-phosphorylated htau40 
(Fig. 2). Phosphorylation by SAPK2a and SAPK2b resulted 
in intermediate reductions in the gel mobility of tau (Fig. 2). 
Tau phosphorylated by each of the five SAP kinases was 
strongly immunoreactive with AT270, a phosphorylation-de-
pendent monoclonal antibody which recognises tau phos-
phorylated at T181 [30] (Fig. 2). Phosphorylated tau was 
also immunoreactive with AP422, a monoclonal anti-tau anti-
Table 1 
Rates of tau phosphorylation by SAP kinases relative to myelin ba-

























SAP kinases were activated in vitro and phosphorylation of myelin 
basic protein, ATF2 and tau (each at 2 \iM) studied at a SAPK 
concentration of 0.2 U/ml (n = 5). The data for phosphorylation of 
ATF2 by SAPK2a, SAPK2b, SAPK3 and SAPK4 are taken from 
[24]. n.d., not determined. 
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Fig. 2. Phosphorylation of recombinant tau protein (expressed from clone htau40) with 1 U/ml SAPKly, SAPK2a, SAPK2b, SAPK3 and 
SAPK4. Immunoblots were incubated with anti-tau serum 134 and the phosphorylation-dependent monoclonal anti-tau antibodies AT270, 
AT8, AD2 and AP422. Lanes: 1, htau40; 2, htau40+SAPK. 
body which recognises tau phosphorylated at S422 [10] (Fig. 
2). However, whereas tau phosphorylated by SAPK4, SAPK3 
and SAPK2b reacted strongly with AP422, tau phosphoryl-
ated with SAPK2a and SAPKly reacted only weakly. Tau 
phosphorylated by SAPK4 and SAPK3 also reacted strongly 
with AT8, a monoclonal anti-tau antibody which recognises 
tau phosphorylated at S202 and T205 [31] (Fig. 2). Tau phos-
phorylated by SAPK2b and SAPK2a also reacted with AT8, 
whereas AT8 failed to recognise tau phosphorylated by 
SAPKly. Similar results were obtained with AD2, a mono-
clonal anti-tau antibody that recognises tau phosphorylated at 
S396 and S404 [32] (Fig. 2). Tau phosphorylated by SAPK3 
and SAPK4 reacted strongly with AD2, whereas tau phos-
phorylated by SAPKly failed to react. We also used mono-
clonal antibody M4 which is specific for tau phosphorylated 
at T231 [10,33]. However, we failed to observe M4 immuno-
reactivity upon phosphorylation of tau by SAP kinases. Sim-
ilarly, tau phosphorylated by SAP kinases failed to react with 
12E8, a monoclonal antibody which recognises tau phos-
phorylated at S262 and/or S356 [34] (data not shown). 
Sulphated glycosaminoglycans are known to stimulate tau 
phosphorylation by a number of protein kinases [10,35,36] 
and to induce the formation of tau filaments very similar to 
the PHFs from Alzheimer's disease brain [28]. We therefore 
examined the effects of heparin and dextran sulphate on tau 
phosphorylation by SAP kinases. Addition of 100 |xg/ml hep-
arin (data not shown) or dextran sulphate to the phosphor-
ylation reaction increased tau phosphorylation by SAPKly, 
SAPK3 and SAPK4 (Fig. 3). Tau phosphorylated by SAPKly 
additionally became immunoreactive with antibodies AT8 and 
AD2 (data not shown). The effect of heparin and dextran 
sulphate was particularly pronounced on tau phosphorylated 
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Fig. 3. Phosphorylation of recombinant tau protein (expressed from 
clone htau40) with 1 U/ml SAPKly, SAPK2a, SAPK2b, SAPK3 
and SAPK4, in presence of 100 ug/ml dextran sulphate (DS). Immu-
noblots were incubated with anti-tau serum 134 and the phosphoryl-
ation-dependent monoclonal anti-tau antibody M4. Lanes: 
l,htau40+DS; 2, htau40+DS+SAPK. 
by SAPK4, with an eight-fold stimulation of the initial rate of 
tau phosphorylation and the incorporation of 16 mol phos-
phate/mol tau after 18 h. Sulphated glycosaminoglycans had 
no significant effect on phosphorylation of MBP by SAPK4. 
In contrast, phosphorylation of tau by SAPK2a and SAPK2b 
was reduced in the presence of heparin (data not shown) and 
dextran sulphate (Fig. 3). Phosphorylation of tau by SAPKly, 
SAPK3 and SAPK4 in presence of dextran sulphate resulted 
in the appearance of the epitope of antibody M4, indicative of 
phosphorylation at T231 (Fig. 3). 
We tested whether phosphorylation of htau40 by SAPK3 
and SAPK4 to high stoichiometries has an effect on the ability 
of tau to promote microtubule assembly. Tau phosphorylated 
by SAPK3 and SAPK4 promoted microtubule assembly ap-
proximately five-fold less efficiently than non-phosphorylated 
htau40, as judged by initial rates (Fig. 4). Phosphorylation of 
tau by SAPK4 was slightly more inhibitory than phosphoryl-
ation by SAPK3 (Fig. 4), in accordance with tau being a 
somewhat better substrate for SAPK4. 
4. Discussion 
SAP kinases are MAP kinase family members which are 
activated by a wide variety of cellular stresses, by bacterial 
lipopolysaccharide and by the pro-inflammatory cytokines in-
terleukin-1 and tumour necrosis factor [20]. The activation of 
SAP kinases requires their phosphorylation on a threonine 
and a tyrosine residue, both phosphorylations being catalysed 
by SAP kinase kinases (SKKs) that are themselves dependent 
on serine/threonine phosphorylation for activity. SAPK1 is 
activated by SKK1 (also called MKK4), SAPK2a is activated 
by SKK2 (also called MKK3) and SKK3 (also called 
MKK6), whereas SAPK2b, SAPK3 and SAPK4 are activated 
by SKK3 [20]. Where examined, SAP kinase mRNAs are ex-
pressed in brain [21,23,24,37,38]. However, their normal role 
and the factors that stimulate their activity in this tissue are 
not well understood. 
In this paper we show that the SAP kinases SAPKly, SAP-
K2a, SAPK2b, SAPK3 and SAPK4 phosphorylate tau pro-
tein to various extents, as judged by relative initial rates of 
phosphorylation, incorporation of phosphate after extended 
periods of incubation, reduced gel mobility of phosphorylated 
tau and the production of epitopes of phosphorylation-de-
pendent anti-tau antibodies. By these criteria, tau is a good 
substrate for SAPK4 and SAPK3, a reasonable substrate for 
SAPK2b and a relatively poor substrate for SAPK2a and 
SAPKly. SAPK1 exists as multiple isoforms that are pro-
duced from three different genes by alternative mRNA splic-
ing [39]. A very recent study has shown that tau is also a 
relatively poor substrate for non-activated recombinant rat 
SAPKlß [40]. It remains to be seen whether tau is a better 
substrate for other isoforms of activated SAPK1. Initial rates 
of phosphorylation showed that tau is as good a substrate for 
SAPK4 as MBP which is used as the standard substrate for 
this protein kinase. This suggests that SAPK4 may play a 
physiological role in tau phosphorylation. Following an 18 
h incubation with SAPK4, tau incorporated 14 mol phos-
phate/mol tau and showed a marked reduction in gel mobility. 
This resulted in the production of the epitopes of the phos-
phorylation-dependent anti-tau antibodies AT270, AT8, AD2 
and AP422, indicating phosphorylation of T181, S202, T205, 
S396, S404 and S422 in tau. These antibodies recognise spe-
cific S/T-P sites in tau, in accordance with the known specif-
icities of SAP kinases. Phosphorylation of tau by SAPKly 
only produced the epitopes of AT270 and AP422, whereas 
phosphorylation by SAPK2a, SAPK2b and SAPK3 resulted 
in the appearance of the epitopes of all the above antibodies, 
albeit to variable intensities. Interestingly, all five SAP kinases 
phosphorylated S422 in tau, a site which is phosphorylated in 
PHF-tau, but not in biopsy-derived adult human brain tau 












Fig. 4. Effects of phosphorylation of recombinant tau protein (expressed from clone htau40) with 1 U/ml SAPK3 and SAPK4 on promotion of 
microtubule assembly, as compared to non-phosphorylated htau40 (Control). 
[10]. We have shown previously that MAP kinase also phos-
phorylates this site, whereas GSK3ß and NCLK fail to do so 
[10]. Of the available phosphorylation-dependent anti-tau 
antibodies of known epitope with a specificity for S/T-P sites, 
only antibody M4 failed to react with tau phosphorylated by 
SAP kinases. Similar results were obtained previously with tau 
phosphorylated by MAP kinase [30]. 
It is well established that phosphorylation of tau by a num-
ber of protein kinases is strongly stimulated in the presence of 
heparin [10,35,36] and we have shown recently that sulphated 
glycosaminoglycans also induce bulk assembly of tau into 
filaments with a morphology similar to the PHFs from Alz-
heimer's disease brain [28]. We therefore examined the effects 
of heparin and dextran sulphate on tau phosphorylation by 
SAP kinases. Phosphorylation by SAPKly, SAPK3 and 
SAPK4 was strongly stimulated, resulting in an eight-fold 
stimulation of the initial rate of tau phosphorylation by 
SAPK4. In contrast, phosphorylation of tau by SAPK2a 
and SAPK2b was markedly inhibited by heparin and dextran 
sulphate. Addition of sulphated glycosaminoglycans resulted 
in the appearance of the epitope of antibody M4 when tau 
was phosphorylated with SAPKly, SAPK3 and SAPK4, in-
dicating phosphorylation of T231. 
These findings extend previous results indicating different in 
vitro substrate specificities of individual SAP kinases. SAPK1 
is the only member of this family to phosphorylate the acti-
vation domain of c-Jun [21]. The known substrate specificities 
of SAPK4 resemble those of SAPK3 in that, while both en-
zymes phosphorylate a number of proteins (including the ac-
tivation domains of several transcription factors) at similar 
rates to SAPK2a and SAPK2b, they are far less effective in 
activating MAP kinase-activated protein kinase-2 (MAPKAP-
K2) and MAPKAP-K3 than either SAPK2a or SAPK2b [24]. 
Moreover, the pyridinyl-imidazole compounds SB 203580 and 
SB 202190 [41] inhibit SAPK2a and SAPK2b, but not SAPK3 
and SAPK4 [24]. Here we show that tau protein is a better 
substrate for SAPK4 and SAPK3 than for SAPK2b, SAPK2a 
and SAPKly. 
Depending on the isoform, the microtubule-binding region 
of tau consists of three or four repeats of 31 or 32 amino acids 
each [29]. The sequences flanking the repeats are known to 
enhance the affinity of the repeat region for microtubules. In 
particular, the proline-rich region upstream of the repeats, 
which contains many of the S/T-P sites phosphorylated by 
SAP kinases, is essential for tubulin binding in vitro and in 
vivo [42^14]. We therefore examined the effects of phospho-
rylation by SAPK3 and SAPK4 on the ability of tau to pro-
mote microtubule assembly. Phosphorylation of tau by 
SAPK3 and SAPK4 markedly reduced the ability of tau to 
promote microtubule assembly, suggesting that SAP kinases 
could play a role in the regulation of microtubule dynamics in 
normal brain and in the inability of PHF-tau to bind to mi-
crotubules. 
Taken together, the present in vitro findings which indicate 
that tau is phosphorylated by SAP kinases at many S/T-P 
sites, suggest a possible role for SAP kinases in the hyper-
phosphorylation of tau that characterises Alzheimer's disease 
and other neurodegenerative disorders. 
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